Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−14.76 M EUR
0.00 EUR
8.83 M
About GENEURO
Sector
Industry
CEO
Jesús Martin-Garcia
Website
Headquarters
Plan-les-Ouates
Founded
2006
ISIN
CH0308403085
FIGI
BBG00BWQN2D8
GeNeuro SA is a clinical stage company, which engages in the research and development of pharmaceutical products. It develops treatments against neurological disorders and autoimmune diseases. The firm's lead therapeutic candidate, temelimab, is a humanized monoclonal antibody that neutralizes a pathogenic human endogenous retroviruses (HERV) protein of the W family called pHERV-W env that has been identified as a factor in the onset and development of autoimmune diseases. The company was founded by Herve Perron and Jesus Martin-Garcia in 2006 and is headquartered in Plan-les-Ouates, Switzerland.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of GNRO is 0.0760 EUR — it has decreased by −15.37% in the past 24 hours. Watch GENEURO stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on EURONEXT exchange GENEURO stocks are traded under the ticker GNRO.
GNRO stock has fallen by −23.23% compared to the previous week, the month change is a 6.15% rise, over the last year GENEURO has showed a −92.48% decrease.
GNRO reached its all-time high on Apr 15, 2016 with the price of 13.7200 EUR, and its all-time low was 0.0428 EUR and was reached on Dec 4, 2024. View more price dynamics on GNRO chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
GNRO stock is 31.58% volatile and has beta coefficient of 1.72. Track GENEURO stock price on the chart and check out the list of the most volatile stocks — is GENEURO there?
Today GENEURO has the market capitalization of 2.24 M, it has decreased by −56.11% over the last week.
Yes, you can track GENEURO financials in yearly and quarterly reports right on TradingView.
GENEURO is going to release the next earnings report on Apr 7, 2025. Keep track of upcoming events with our Earnings Calendar.
No, GNRO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 22, 2024, the company has 19.00 employees. See our rating of the largest employees — is GENEURO on this list?
Like other stocks, GNRO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GENEURO stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GENEURO technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GENEURO stock shows the sell signal. See more of GENEURO technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.